Dimitrios Papadopoulos1, Dimos-Dimitrios D Mitsikostas2. 1. Multiple Sclerosis Centre and Neurology Section, Athens Medical Centre - Paleo Phaliro Clinic, 175-62, Athens, Greece. 2. 1st Neurology Department, Aeginition Hospital, Medical School, National and Kapodistrian University of Athens, 72-74 V. Sofia's Avenue, 11528, Athens, Greece. dmitsikostas@med.uoa.gr.
Abstract
BACKGROUND: The likelihood to help or harm (LHH) is an absolute measure of the benefit versus risk profile of a medication, which can be used to assess the potential for benefit versus harm of different disease-modifying treatments (DMTs) for relapsing multiple sclerosis (R-MS) and facilitate clinical decision-making. OBJECTIVE: The objective of this study was to assess absolute differences in benefit:risk ratios of oral DMTs for R-MS, using LHH analysis with no evidence of disease activity (NEDA) as beneficial outcome. DESIGN/ METHODS: The number needed to treat for a paient to achieve NEDA (NNTBNEDA) was used as an effect size metric of efficacy and the number needed to treat for a patient to experience an adverse event (NNTHAE), a serious adverse event (NNTHSAE), or treatment discontinuation due to an adverse event (NNTHAE-D) were used as measures of risk. The LHH-which is the ratio of NNTH:NNTB-values were calculated from published phase III trial data for oral DMTs. RESULTS: The values for likelihood to achieve NEDA than experience any AE ratio (LHH(AE/NEDA)) were 3.5, 6.8, 12.5 and 2.6, the likelihood to achieve NEDA than experience a SAE ratio (LHH(SAE/NEDA)) values were 13.0, 3.5, 23.5 and 2.7, and the likelihood to achieve NEDA versus discontinue treatment (LHH(AE-D/NEDA)) values were 17.7, 6.5, 4.6 and 3.0 for cladribine, dimethyl-fumarate, fingolimod, and teriflunomide, respectively. CONCLUSIONS: With all of the oral DMTs examined, R-MS patients are more likely to achieve NEDA than experience any adverse event.
BACKGROUND: The likelihood to help or harm (LHH) is an absolute measure of the benefit versus risk profile of a medication, which can be used to assess the potential for benefit versus harm of different disease-modifying treatments (DMTs) for relapsing multiple sclerosis (R-MS) and facilitate clinical decision-making. OBJECTIVE: The objective of this study was to assess absolute differences in benefit:risk ratios of oral DMTs for R-MS, using LHH analysis with no evidence of disease activity (NEDA) as beneficial outcome. DESIGN/ METHODS: The number needed to treat for a paient to achieve NEDA (NNTBNEDA) was used as an effect size metric of efficacy and the number needed to treat for a patient to experience an adverse event (NNTHAE), a serious adverse event (NNTHSAE), or treatment discontinuation due to an adverse event (NNTHAE-D) were used as measures of risk. The LHH-which is the ratio of NNTH:NNTB-values were calculated from published phase III trial data for oral DMTs. RESULTS: The values for likelihood to achieve NEDA than experience any AE ratio (LHH(AE/NEDA)) were 3.5, 6.8, 12.5 and 2.6, the likelihood to achieve NEDA than experience a SAE ratio (LHH(SAE/NEDA)) values were 13.0, 3.5, 23.5 and 2.7, and the likelihood to achieve NEDA versus discontinue treatment (LHH(AE-D/NEDA)) values were 17.7, 6.5, 4.6 and 3.0 for cladribine, dimethyl-fumarate, fingolimod, and teriflunomide, respectively. CONCLUSIONS: With all of the oral DMTs examined, R-MS patients are more likely to achieve NEDA than experience any adverse event.
Authors: Peter A Calabresi; Ernst-Wilhelm Radue; Douglas Goodin; Douglas Jeffery; Kottil W Rammohan; Anthony T Reder; Timothy Vollmer; Mark A Agius; Ludwig Kappos; Tracy Stites; Bingbing Li; Linda Cappiello; Philipp von Rosenstiel; Fred D Lublin Journal: Lancet Neurol Date: 2014-03-28 Impact factor: 44.182
Authors: Mark S Freedman; Xavier Montalban; Aaron E Miller; Catherine Dive-Pouletty; Steven Hass; Karthinathan Thangavelu; Thomas P Leist Journal: Mult Scler Relat Disord Date: 2016-11-03 Impact factor: 4.339
Authors: Christian Confavreux; Paul O'Connor; Giancarlo Comi; Mark S Freedman; Aaron E Miller; Tomas P Olsson; Jerry S Wolinsky; Teresa Bagulho; Jean-Luc Delhay; Deborah Dukovic; Philippe Truffinet; Ludwig Kappos Journal: Lancet Neurol Date: 2014-01-23 Impact factor: 44.182